Bortezomib (Velcade) in combination with dexamethasone eor relapsed or refractory myeloma
https://doi.org/10.17650/1818-8346-2007-0-4-61-66
Abstract
Theproteasome inhibitor bortezomib (Velcade) has demonstrated clinical activity in patients with multiple myeloma (MM). We report the activity of borte-zomib plus dexamethasone in 60patients with relapsed and refractory myeloma. The patients had a median age of 65 years (range, 38—79 years). The median number of previous treatments was 3 (range, 1-9). For patients who received bortezomib plus dexamethasone the overall response rate was 73%. 38% patients achieved CR. CR in patients receiving bortezomib plus dexamethasone earlier vs later (≤ 3 и ≥ 4 line chemotherapy) were: 48% vs 27,5%. Bortezomib is active in patients with relapsed MM, including elderly patients. Side effects were predictable and manageable; principal toxicities were hematological, gastrointestinal, and peripheral neuropathy. The most common adverse events reported were asthenia (52%), neuropathy (53%), thrombocytopenia (32%), anemia (30%). Neuropathy greater than grade 2 was more frequent in patients who received 3 or more prior therapy regimens.
About the Authors
S. S. Bessmeltsev
Russian Research Institute of Hematology and Transfusiology
Russian Federation
Russian Federation
L. V. Stelmashenko
Russian Research Institute of Hematology and Transfusiology
Russian Federation
Russian Federation
E. I. Podoltseva
City Hospital 31
Russian Federation
Russian Federation
E. V. Kariagina
City Hospital 15
Russian Federation
Russian Federation
G. N. Salogub
St. Petersburg State Pavlov Medical University
Russian Federation
Russian Federation
А. S. Nisamutdinova
Alexandrovsky Hospital
Russian Federation
Russian Federation
L. M. Matuhina
Road Clinic Hospital
Russian Federation
Russian Federation
St-Petersburg
K. M. Abdulkadyrov
Russian Research Institute of Hematology and Transfusiology
Russian Federation
Russian Federation
References
1. Бессмельцев С.С., Абдулкадыров К.М. Множественная миелома. Современный взгляд на проблему. Алматы; 2007.
2. Sonneveld P. Multidrug resistance in haematological malignancies. J Intern Med 2000;247:521—34.
3. Montagut C., Rovira A., Mellado B. et al. Preclinical and clinical development of the proteasome inhibitor bortezomib in cancer treatment. Drugs Today (Barc) 2005;41:299—315.
4. Karin M., Cao Y., Greten F.R., Li Z.W. NF-kappaB in cancer: from innocent bystander to major culprit. Nat Rev Cancer 2002;2:301—10.
5. Mitsiades N., Mitsiades C. S., Richardson P. G. et al. The proteasome inhibitor PS-341 potentiates sensitivity of multiple myeloma cells to conventional chemotherapeutic agents: therapeutic applications. Blood 2003;101:2377—80.
6. Richardson P.G., Barlogie B., Berenson J. et al. A phase 2 study of bortezomib in relapsed, refractory myeloma. N Engl J Med 2003;348:2609—17.
7. Richardson P.G., Sonneveld P., Schuster M.W. et al. Bortezomib or high-dose dexamethasone for relapsed multiple myeloma. N Engl J Med 2005;352: 2487—98.
8. Kropff M.H., Bisping G., Wenning D. et al. Bortezomib in combination with dexamethasone for relapsed multiple myeloma. Leuk Res 2005;29:587—90.
9. Бессмельцев С.С., Стельмашенко Л.В., Подольцева Э.И. и др. Первый отечественный опыт применения бортезомиба (велкейда) в лечении рефрактерных и рецидивирующих форм множественной миеломы. Вестн гематол 2007;(1):16—23.
10. Blade J., Samson D., Reece D. et al. Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and haemopoietic stem cell transplantation. Br J Haematol 1998;102:1115—23.
11. Kurabayashi H., Kubota K., Tsuchiya J. et al. Prognostic value of morphological classifications and clinical variables in elderly and young patients with multiple myeloma. Ann Hematol 1999;78:19—23.
12. Alexanian R. Combination chemotherapy for multiple myeloma. Cancer 1972;30:382—6.
13. Mateos M.V., Hernandez J.M., Hernandez M.T. et al. Bortezomib plus melphalan and prednisone in elderly untreated patients with multiple myeloma: results of a multicenter phase I/II study. Blood 2006;108(7):2165—72.
14. Ciolli S., Leoni F., Gigli F. et al. Low dose velcade, thalidomide and dexamethasone (LD-VTD): An effective regimen for relapsed and refractory multiple myeloma patients. Leuk Lymphoma 2006;47:171—3.
15. Palumbo A., Avonto I., Falco P. et al. Novel treatment approaches in multiple myeloma. In: Hematology education (education program for the 12th Congress of the European Hematology Association, Viena, June 7—10; 2007. p. 108—14.
16. Бессмельцев С.С. Новые противоопухолевые препараты в лечении множественной миеломы. Вестн гематол 2006;2(2):27—41.
17. Jagannath S., Barlogie B., Berenson J. et al. A phase 2 study of two doses of borte-zomib in relapsed or refractory myeloma. Br J Haematol 2004;127:165—72.
18. Berenson J.R., Jagannath S., Barlogie B. et al. Safety of prolonged therapy with bortezomib in relapsed or refractory multiple myeloma. Cancer 2005;104(10):2141—8.
19. Lonial S., Waller E.K., Richardson P.G. et al. Risk factors and kinetics of thrombocytopenia associated with bortezomib for relapsed, refractory multiple myeloma. Blood 2005;106:3777—84.
20. Bang S.M., Lee J.H., Yoon S.S. et al. A multicenter retrospective analysis of adverse events in Korean patients using bortezomib for multiple myeloma. Int J Hematol 2006;83:309—13.
Review
For citations:
Bessmeltsev S.S., Stelmashenko L.V., Podoltseva E.I., Kariagina E.V., Salogub G.N., Nisamutdinova А.S., Matuhina L.M., Abdulkadyrov K.M. Bortezomib (Velcade) in combination with dexamethasone eor relapsed or refractory myeloma. Oncohematology. 2007;(4):61-66. (In Russ.) https://doi.org/10.17650/1818-8346-2007-0-4-61-66
Views:
240
Email this article 